Elucidating the exact pharmacological mechanism of action (MOA) of Normally taking place compounds could be demanding. While Tarselli et al. (60) created the initial de novo synthetic pathway to conolidine and showcased that this Normally developing compound successfully suppresses responses to both of those chemically induced and inflammation-deri